Table 2.
PCT value of severe or deceased COVID-19 patients in different clinical studies.
| Studies | Patients’ categories | Number of patientsa | PCT value ng/mL (n, %) |
P value | ||||
|---|---|---|---|---|---|---|---|---|
| Rangeb | >0.05 | >0.1 | >0.25 | >0.50 | ||||
| Li et al [115] | Dead | 21 | 0.36 (0.13, 1.91) | NA | 19, 90.5 | 12, 57 | 9, 42 | – |
| Zhang et al [10] | Dead | 69 | 0.3 (0.1−1.1) | NA | 56, 81.2 | NA | NA | – |
| Chen et al [121] | Dead | 96 | 0.33 (0.14−0.65) | NA | NA | NA | 27, 28.1 | NA |
| Recovered | 140 | 0.05 (0.03−0.08) | NA | NA | NA | 3, 2.1 | ||
| Guan et al [8] | Severe | 173 | NA | NA | NA | NA | 12, 24.0 | NA |
| Non-severe | 926 | NA | NA | NA | NA | 19, 3.7 | ||
| Xiong et al [122] | Severe | 21 | 0.33 ± 0.27 | NA | NA | NA | NA | <.05d |
| Mild | 18 | 0.13 ± 0.11 | NA | NA | NA | NA | ||
| Yuan et al [123] | Severe | 31 | 0.05 (0.01−2.1) | NA | NA | NA | NA | .000 |
| Non-severe | 192 | 0.01 (0.01−0.4) | NA | NA | NA | NA | ||
| Zhang et al [124] | Severe | 50 | 0.1 (0.06−0.3) | NA | 25, 50.0 | NA | NA | <.001d |
| Non-severe | 68 | 0.05 (0.03−0.1) | NA | 16, 23.5 | NA | NA | ||
| Huang et al [61] | ICU | 12 | 0.1 (0.1−0.4) | NA | 6, 50.0 | 3, 25.0 | 3, 25.0 | .031d |
| Non-ICU | 27 | 0.1 (0.1−0.1) | NA | 6, 22.2 | 2, 7.4 | 0 | ||
| Wang et al [125] | ICU | 36 | NA | 27, 75.0 | NA | NA | NA | <.001e |
| Non-ICU | 102 | NA | 22, 21.6 | NA | NA | NA | ||
| Wan et al [126] | Severe | 40 | 0.11 (0.08−0.16) | NA | 19, 47.5 | 4, 10.0 | 1, 2.5 | <.0001d |
| Mild | 95 | 0.04 (0.03−0.06) | NA | 6, 6 | 0 | 0 | ||
| Peng et al [127] | Severe | 16 | 0.20 (0.15, 0.48) | NA | NA | NA | NA | <.001d |
| General | 96 | 0.11 (0.06, 0.20) | NA | NA | NA | NA | ||
| Qin et al [63] | Severe | 286 | 0.1 (0.0−0.2) | NA | NA | NA | NA | <.001d |
| Non-severe | 166 | 0.05 (0.03−0.09) | NA | NA | NA | NA | ||
| Li et al [128] | Critically severe | 16 | 0.44 ± 0.512 | NA | NA | NA | NA | .008d |
| Severe | 56 | 0.14 ± 0.353 | NA | NA | NA | NA | ||
| Moderate | 60 | 0.08 ± 0.279 | NA | NA | NA | NA | ||
| Wang et al [73] | SpO2 < 90 % | 14 | 0.13 (0.13−0.15) | NA | NA | NA | 0, 0 | .78d |
| SpO2 ≥ 90 % | 55 | 0.13 (0.13−0.15) | NA | NA | NA | 4, 8 | ||
| Shi et al [129] | With cardiac injury | 82 | 0.27 (0.10−1.22) | NA | NA | NA | NA | <.001d |
| Without | 334 | 0.06 (0.03−0.10) | NA | NA | NA | NA | ||
| Wu et al [130] | With ocular symptoms | 12 | NA | 8, 66.7 | NA | NA | NA | .03e |
| Without | 25 | NA | 7, 28.0 | NA | NA | NA | ||
| Qiu et al [116] | Moderate pediatric | 19 | 0.32 ± 0.19 | 5, 26.3 | NA | NA | NA | .0039d |
| Mild pediatric | 17 | 0.15 ± 0.13 | 1, 5.9 | NA | NA | NA | ||
| Sun et al [131] | Pediatric | 8 | 0.085 (0.05, 0.128) | 5, 62.5 | 3, 37.5 | 1, 12.5 | 1, 12.5 | – |
| Xia et al [132] | Pediatric | 20 | NA | 16, 80 | NA | NA | NA | – |
aNumber of patients with the record of PCT. b PCT values in different studies were expressed as different forms, including mean ± SD, median (IQR), and median (mix-max). c PCT value≥0.05. d P-value of the comparison between the PCT value of two groups. e P-value of the comparison between the proportion of the patients with increased PCT value in two groups. The tests with a P-value of <0.05 are considered statistically significant.